CDY.ASX
Cellmid set to commercialise 15 minute diagnostic test for COVID-19
Life sciences company Cellmid (ASX: CDY) is set to come out of its self-imposed trading halt on Monday with news that it will commercialise a rapid test capable of detecting coronavirus (COVID-19) within 15 minutes. First developed in China by biotech company Guangzhou Wondfo Biotech, the diagnostic test is set to be used as a […]
Cellmid prepares to receive Chinese patent covering évolis range
Life sciences company Cellmid (ASX: CDY) has told the market it is tentatively expecting to receive a patent from the Chinese Patent Office for its évolis brand in the very near future. Earlier today, Cellmid said that Chinese authorities had issued a notice of intention to grant in relation to its patent titled “Method of treatment of […]
Cellmid launches evolis hair products into Europe and China via new distribution agreements
Cellmid (ASX: CDY) has launched into Europe after securing a distribution agreement with Douglas GmbH for its evolis professional anti-aging hair care and hair loss products, while at the same time collaring a distribution agreement in China with Aeon International for the same products. Douglas is a leading German beauty retailer and will initially focus […]
Cellmid predicts record second quarter revenue after successful Japanese sales campaign
Australian life sciences company Cellmid (ASX: CDY) has reaped a revenue of approximately $1.1 million from a scheduled sales event for its Jo-Ju hair growth products in Japan. The figure will contribute to the company’s expected record sales revenue for second quarter 2019 of more than $2m. Cellmid’s promotion of the repackaged Jo-Ju line on […]
